Browse Clinical Publication Articles by Topic

Timing of Anticoagulation Administration Following Atrial Fibrillation-Associated Stroke

A prospective, blinded, randomized study of early vs. later administration of oral anticoagulation after ischemic stroke in patients with atrial fibrillation calibrated by cerebral imaging showed no significant difference in 30-day outcomes.

Researchers Report on the Efficacy of the Subcutaneous Implantable Cardioverter-Defibrillator

An FDA-mandated post-approval study of the subcutaneous cardioverter-defibrillator system in a real-world population revealed excellent safety and efficacy over five years.

Oral Penicillin Challenge vs. Skin Testing: Diagnosing Low-Risk Patients with Reported Penicillin Allergy

In a comparison of direct oral penicillin challenge in low-risk patients to skin testing followed by oral challenge, researchers reported no significant differences. Direct oral penicillin challenge appears to be a safe and effective way to delabel a penicillin allergy.

Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant

More than 500 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment vs. placebo.

Statins Might Lower Risk of Recurrent Stroke

Patients in Denmark who suffered an intracerebral hemorrhage and were taking cholesterol-lowering medication were less likely to experience another stroke.

An RNA Shot for Hypertension?

One dose of a new RNA-based drug administered by subcutaneous injection, which blocks hepatic angiotensinogen production, resulted in sustained reductions in blood pressure in patients with hypertension for up to 24 weeks without any serious adverse effects.

Is the Combination of a GLP-1 Agonist and a SGLT2 Inhibitor Safe?

Adding a GLP-1 RA in a subgroup of type 2 diabetes patients on baseline SGLT2 inhibitor therapy revealed GLP-1 RA reduces major adverse cardiovascular event rates, regardless of baseline SGLT2 use.

The Hemodynamic Effects of an SGLT2 Inhibitor in Heart Failure with Preserved Ejection Fraction

The authors of a small, placebo-controlled study of 24 weeks of dapagliflozin therapy in patients with heart failure with preserved ejection fraction reported reductions in pulmonary capillary wedge pressure, which may explain the reductions in heart failure hospitalizations or cardiovascular death in larger randomized outcome trials.

High-Impact Clinical Trials from the European Society of Cardiology Congress 2023

The following is an overview of important cardiology research presented Aug. 25 through Aug. 28 in Amsterdam and online during the ESC Congress 2023.

Is Planned Complete Revascularization After Myocardial Infarction Wise for Older Patients?

Among patients at least age 75 years presenting with acute myocardial infarction and multivessel coronary disease, physiology-guided complete revascularization led to a lower risk of major adverse cardiovascular events at one year vs. culprit lesion-only percutaneous coronary intervention.